OrthoPediatrics/$KIDS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About OrthoPediatrics
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
- Ticker
- $KIDS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 602
- Headquarters
- Warsaw, United States
- Website
- www.orthopediatrics.com
OrthoPediatrics Metrics
BasicAdvanced
$806M
-
-$1.42
0.99
-
Price and volume
Market cap
$806M
Beta
0.99
52-week high
$32.62
52-week low
$14.42
Average daily volume
301K
Financial strength
Current ratio
4.552
Quick ratio
1.865
Long term debt to equity
0.318
Total debt to equity
0.327
Interest coverage (TTM)
-2.34%
Profitability
EBITDA (TTM)
1.129
Gross margin (TTM)
73.76%
Net profit margin (TTM)
-12.83%
Operating margin (TTM)
-8.15%
Effective tax rate (TTM)
-0.88%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-2.68%
Return on equity (TTM)
-9.84%
Valuation
Price to revenue (TTM)
2.789
Price to book
2.38
Price to tangible book (TTM)
5.49
Price to free cash flow (TTM)
231.696
Free cash flow yield (TTM)
0.43%
Free cash flow per share (TTM)
0.133
Growth
Revenue change (TTM)
16.15%
Earnings per share change (TTM)
-27.34%
3-year revenue growth (CAGR)
22.95%
3-year earnings per share growth (CAGR)
12.40%
What the Analysts think about OrthoPediatrics
Analyst ratings (Buy, Hold, Sell) for OrthoPediatrics stock.
Analyst projections of the future price of OrthoPediatrics stock.
Bulls say / Bears say
Third-quarter revenue rose 19% to a record $72.7 million, with growth in both major product areas, and OrthoPediatrics raised its 2026 revenue outlook to $270–273 million. The strong result points to continuing demand and share gains. (OrthoPediatrics)
Profitability indicators improved: adjusted EBITDA reached a quarterly record of $6.9 million, and the company generated $1.6 million of free cash flow after using $3.4 million a year earlier. Management still expects breakeven or better free cash flow for 2026. (OrthoPediatrics)
New products are showing signs of clinical uptake: the 3P Hip system completed more than 350 implantations during its limited launch before becoming broadly available in the US. Further launches could extend the company’s growth if surgeons adopt them. (OrthoPediatrics)
The company remains loss-making on a GAAP basis, reporting a $5.9 million net loss in the third quarter despite record adjusted EBITDA. Sustained profitability has yet to be demonstrated. (OrthoPediatrics)
The business ties up substantial capital in inventory and consigned surgical sets: inventory was about $142 million at September’s end, while cash, short-term investments and restricted cash fell to $44.9 million from $62.9 million at year-end. That leaves less financial room to fund expansion without improving cash generation or using financing. (SEC, SEC)
Management says the number of sets available for 3P Hip remains limited and it is avoiding more aggressive cash deployment. That could slow adoption of new products even where hospitals and surgeons show interest. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
OrthoPediatrics Financial Performance
Revenues and expenses
OrthoPediatrics Earnings Performance
Company profitability
Upcoming events
No upcoming events
OrthoPediatrics News
AllArticlesVideos
Funds containing OrthoPediatrics
Fund name | Fund size | $KIDS weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.